Low NOx heavy fuel combustor concept program addendum: Low/mid heating value gaseous fuel evaluation

The combustion performance of a rich/quench/lean (RQL) combustor was evaluated when operated on low and mid heating value gaseous fuels. Two synthesized fuels were prepared having lower heating values of 10.2 MJ/cu m. (274 Btu/scf) and 6.6 MJ/cu m (176 Btu/scf). These fuels were configured to be representative of actual fuels, being composed primarily of nitrogen, hydrogen, carbon monoxide, and carbon dioxide. A liquid fuel air assist fuel nozzle was modified to inject both of the gaseous fuels. The RQL combustor liner was not changed from the configuration used when the liquid fuels were tested. Both gaseous fuels were tested over a range of power levels from 50 percent load to maximum rated power of the DDN Model 570-K industrial gas turbine engine. Exhaust emissions were recorded for four power level at several rich zone equivalence ratios to determine NOx sensitivity to the rich zone operating point. For the mid Btu heating value gas, ammonia was added to the fuel to simulate a fuel bound nitrogen type gaseous fuel. Results at the testing showed that for the low heating value fuel NOx emissions were all below 20 ppmc and smoke was below a 10 smoke number. For the mid heating value fuel, NOx emissions were in the 50 to 70 ppmc range with the smoke below a 10 smoke number

Analytical fuel property effects--small combustors

The consequences of using broad-property fuels in both conventional and advanced state-of-the-art small gas turbine combustors are assessed. Eight combustor concepts were selected for initial screening, of these, four final combustor concepts were chosen for further detailed analysis. These included the dual orifice injector baseline combustor (a current production 250-C30 engine combustor) two baseline airblast injected modifications, short and piloted prechamber combustors, and an advanced airblast injected, variable geometry air staged combustor. Final predictions employed the use of the STAC-I computer code. This quasi 2-D model includes real fuel properties, effects of injector type on atomization, detailed droplet dynamics, and multistep chemical kinetics. In general, fuel property effects on various combustor concepts can be classified as chemical or physical in nature. Predictions indicate that fuel chemistry has a significant effect on flame radiation, liner wall temperature, and smoke emission. Fuel physical properties that govern atomization quality and evaporation rates are predicted to affect ignition and lean-blowout limits, combustion efficiency, unburned hydrocarbon, and carbon monoxide emissions

Low NOx Heavy Fuel Combustor Concept Program

The development of the technology required to operate an industrial gas turbine combustion system on minimally processed, heavy petroleum or residual fuels having high levels of fuel-bound nitrogen (FBN) while producing acceptable levels of exhaust emissions is discussed. Three combustor concepts were designed and fabricated. Three fuels were supplied for the combustor test demonstrations: a typical middle distillate fuel, a heavy residual fuel, and a synthetic coal-derived fuel. The primary concept was an air staged, variable-geometry combustor designed to produce low emissions from fuels having high levels of FBN. This combustor used a long residence time, fuel-rich primary combustion zone followed by a quick-quench air mixer to rapidly dilute the fuel rich products for the fuel-lean final burnout of the fuel. This combustor, called the rich quench lean (RQL) combustor, was extensively tested using each fuel over the entire power range of the model 570 K engine. Also, a series of parameteric tests was conducted to determine the combustor's sensitivity to rich-zone equivalence ratio, lean-zone equivalence ratio, rich-zone residence time, and overall system pressure drop. Minimum nitrogen oxide emissions were measured at 50 to 55 ppmv at maximum continuous power for all three fuels. Smoke was less than a 10 SAE smoke number

A Precision Measurement of the Neutron Twist-3 Matrix Element d2nd_2^n: Probing Color Forces

Double-spin asymmetries and absolute cross sections were measured at large Bjorken $x$ (0.25 $\le x \le$ 0.90), in both the deep-inelastic and resonance regions, by scattering longitudinally polarized electrons at beam energies of 4.7 and 5.9 GeV from a transversely and longitudinally polarized $^3$He target. In this dedicated experiment, the spin structure function $g_2$ on $^3$He was determined with precision at large $x$, and the neutron twist-three matrix element $d_2^n$ was measured at \left of 3.21 and 4.32 GeV$^2$/$c^2$, with an absolute precision of about $10^{-5}$. Our results are found to be in agreement with lattice QCD calculations and resolve the disagreement found with previous data at \left = 5 GeV$^2$/$c^2$. Combining $d_2^n$ and a newly extracted twist-four matrix element, $f_2^n$, the average neutron color electric and magnetic forces were extracted and found to be of opposite sign and about 30 MeV/fm in magnitude.Comment: Corrected a typo in the author list and Figure 1 legend. 6 pages, 2 figures, 2 table

Measurement of the Neutron Radius of 208Pb Through Parity-Violation in Electron Scattering

We report the first measurement of the parity-violating asymmetry A_PV in the elastic scattering of polarized electrons from 208Pb. A_PV is sensitive to the radius of the neutron distribution (Rn). The result A_PV = 0.656 \pm 0.060 (stat) \pm 0.014 (syst) ppm corresponds to a difference between the radii of the neutron and proton distributions Rn - Rp = 0.33 +0.16 -0.18 fm and provides the first electroweak observation of the neutron skin which is expected in a heavy, neutron-rich nucleus.Comment: 6 pages, 1 figur

FIV establishes a latent infection in feline peripheral blood CD4+ T lymphocytes in vivo during the asymptomatic phase of infection

<p>Abstract</p> <p>Background</p> <p>Feline immunodeficiency virus (FIV) is a lentivirus of cats that establishes a lifelong persistent infection with immunologic impairment.</p> <p>Results</p> <p>In an approximately 2 year-long experimental infection study, cats infected with a biological isolate of FIV clade C demonstrated undetectable plasma viral loads from 10 months post-infection onward. Viral DNA was detected in CD4+CD25+ and CD4+CD25- T cells isolated from infected cats whereas viral RNA was not detected at multiple time points during the early chronic phase of infection. Viral transcription could be reactivated in latently infected CD4+ T cells <it>ex vivo </it>as demonstrated by detectable FIV <it>gag </it>RNA and 2-long terminal repeat (LTR) circle junctions. Viral LTR and <it>gag </it>sequences amplified from peripheral blood mononuclear cells during early and chronic stages of infection demonstrated minimal to no viral sequence variation.</p> <p>Conclusions</p> <p>Collectively, these findings are consistent with FIV latency in peripheral blood CD4+ T cells isolated from chronically infected cats. The ability to isolate latently FIV-infected CD4+ T lymphocytes from FIV-infected cats provides a platform for the study of <it>in vivo </it>mechanisms of lentiviral latency.</p

Pancreatic enzyme replacement therapy in patients with pancreatic cancer: A national prospective study

Objective: UK national guidelines recommend pancreatic enzyme replacement therapy (PERT) in pancreatic cancer. Over 80% of pancreatic cancers are unresectable and managed in non-surgical units. The aim was to assess variation in PERT prescribing, determine factors associated with its use and identify potential actions to improve prescription rates. Design: RICOCHET was a national prospective audit of malignant pancreatic, peri-ampullary lesions or malignant biliary obstruction between April and August 2018. This analysis focuses on pancreatic cancer patients and is reported to STROBE guidelines. Multivariable regression analysis was undertaken to assess factors associated with PERT prescribing. Results: Rates of PERT prescribing varied among the 1350 patients included. 74.4% of patients with potentially resectable disease were prescribed PERT compared to 45.3% with unresectable disease. PERT prescription varied across surgical hospitals but high prescribing rates did not disseminate out to the respective referring network. PERT prescription appeared to be related to the treatment aim for the patient and the amount of clinician contact a patient has. PERT prescription in potentially resectable patients was positively associated with dietitian referral (p = 0.001) and management at hepaticopancreaticobiliary (p = 0.049) or pancreatic unit (p = 0.009). Prescription in unresectable patients also had a negative association with Charlson comorbidity score 5–7 (p = 0.045) or >7 (p = 0.010) and a positive association with clinical nurse specialist review (p = 0.028). Conclusion: Despite national guidance, wide variation and under-treatment with PERT exists. Given that most patients with pancreatic cancer have unresectable disease and are treated in non-surgical hospitals, where prescribing is lowest, strategies to disseminate best practice and overcome barriers to prescribing are urgently required